Idorsia Ltd Logo

Idorsia Ltd

Develops and commercializes small-molecule medicines for CNS, cardiovascular, and immune disorders.

IDIA | SW

Overview

Corporate Details

ISIN(s):
CH0363463438 (+2 more)
LEI:
506700XOVZUB107S5720
Country:
Switzerland
Address:
Hegenheimermattweg 91, 4123 Allschwil
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Idorsia Ltd is a biopharmaceutical company specializing in the discovery, development, and commercialization of innovative small-molecule medicines. The company focuses on addressing unmet medical needs through a diversified and balanced clinical development pipeline. Its portfolio targets multiple therapeutic areas, including central nervous system (CNS), cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia aims to translate scientific innovation into new treatment options and provides robust scientific information and resources to healthcare professionals and patients through a dedicated portal.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Idorsia Ltd filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Idorsia Ltd

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Idorsia Ltd via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-05-11 N/A Non-Executive member Buy None 98,179.90 CHF
2022-05-10 N/A Non-Executive member Buy None 109,660.30 CHF

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.